Disclosed are methods of treating or modulating cachexia and/or increasing lean body mass and/or increasing lower extremity muscle size in a prostate cancer patient comprising administering a therapeutically effective amount of a myostatin antagonist. Further disclosed is the peptibody sequence of the myostatin antagonist, and the formulation of the peptibody.
